In your next study, leverage our agile rare disease team’s decades of combined experience addressing the nuances of clinical development in rare indications. Our full-service solutions are personalized, flexible, and built to balance your needs with those of your patients, patient communities, and stakeholders.
Therapeutic Experts
Countries, All Regions
Every indication and patient population is unique. We’ve collected a wealth of diverse experience across indications and cultivated a proven ability to apply lessons learned into strategies for your unique study.
We’ve worked on rare disease studies across all therapeutic areas, from metabolic to neurology and oncology. With our wide range of experience, we have the ability to support your study no matter how rare your indication.
We’re passionate about making trials work for patients and their families to drive better trial experiences and, ultimately, better trial outcomes.
Every patient counts when it comes to achieving statistical significance. That’s why our solutions are built to access and retain patients throughout the study. Whether you’re looking to work with new sites, utilize cross-border enrollment, or explore new pathways to identify patients, we have you covered.
We’re constantly exploring new and better ways to develop rare disease trials. We partner with patient advocacy organizations around the world, have specialized partnerships with patient registries, and partner with other likeminded organizations to achieve better treatment options for patients.
We’re skilled at supporting endpoint selection and development to ensure data quality, and our in-house clinical assessment team has robust experience with clinical assessments management and training.
With the increased complexity of rare disease research, you can trust we have you covered. Our teams are well-versed in trial logistics, operational solutions, and regulatory engagement, and our scientific and medical expertise is unmatched. No matter the support you need, our experts are accessible, and our senior leadership is available.
Vice President, Therapeutic Strategy Lead, Rare Disease
Executive Director, Therapeutic Strategy Lead, Rare Disease & Cellular and Genetic Medicines
Senior Director, Therapeutic Strategy Lead, Rare Disease
Senior Director, Therapeutic Strategy Lead, Rare Disease
On May 1st, Industry Standard Research (ISR) announced the 2024 Leadership Awards, recognizing Phase 2/3 CROs for comprehensive excellence across their capabilities, compatibility, expertise, quality, and reliability.
In 2023, Worldwide Clinical Trials was named Most Innovative Clinical Research Organization (CRO) by the Triangle Business Journal (TBJ). This awards program celebrates the achievements of individuals and companies making critical advancements in pharmaceuticals, biotech, ag tech, and beyond, in the Triangle region of North Carolina.
Worldwide Clinical Trials, Inc., (Worldwide) the industry’s leading global, midsize, full-service contract research organization (CRO), has been recognized for excellence and honored in five categories in the 2022 CRO Leadership Awards, based on primary market research from Industry Standard Research (ISR) Reports and presented by Clinical Leader and Life Science Leader magazines. This marks the ninth consecutive year that Worldwide has been recognized as a high-performing CRO based on direct survey feedback from pharmaceutical and biotech professionals.
Over 80% of respondents agreed that midsize CROs provide a strong cultural fit while being able to pivot quickly based on changing customer needs.